AroCell presents a robust TK1 blood-test at an international biomarker meeting
Dr. Kiran Kumar Jagarlamudi and Professor Staffan Eriksson presented an abstract showing comparisons between TK1 protein levels in blood donors compared to TK1 levels in patients with different indications, measured with TK 210 ELISA. Patients with myelodysplastic syndrome (MDS, a pre-form of leukemia), breast cancer and prostate cancer were included. In breast and prostate cancer sera, TK1 protein showed a significant correlation with disease stage progression. "The sensitivity and specificity is quite good and clearly superior to that of activity-based TK assays, especially with serum from patients with solid tumors (Jagarlamudi et al., 2015, manuscript in preparation)." says Dr. Jagarlamudi.
(See chart in attached document)
Staffan Eriksson M.D, Ph.D, a co-founder of AroCell concludes: "Thanks to the robust product performance we can now expand our clinical trial activities in cooperation with leading international researchers. Ongoing testing and analyses will most likely further strengthen the scientific foundation for routine use of TK 210 ELISA in cancer disease management in future".
For additional information please contact:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46706-926206
info@arocell.com
About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow-up of cancer patients. AroCell's new technology are based on a patented method to measure TK1 protein levels. Tumors with high cell turnover leak TK1 which now can be measured in blood by AroCell's standard laboratory test; TK 210 ELISA. The test provides valuable clinical information for optimization of treatment strategies and facilitates personalized cancer care. The tests may also assist in monitoring for disease relapse. AroCell is listed at AktieTorget and has about 2 300 shareholders.